Eosinophilic pneumonia medical therapy

Revision as of 20:18, 13 February 2018 by Medhat (talk | contribs)
Jump to navigation Jump to search

Pneumonia Main Page

Eosinophilic pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Eosinophilic pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Eosinophilic pneumonia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Eosinophilic pneumonia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Eosinophilic pneumonia medical therapy

CDC onEosinophilic pneumonia medical therapy

Eosinophilic pneumonia medical therapy in the news

Blogs on Eosinophilic pneumonia medical therapy

Directions to Hospitals Treating Eosinophilic pneumonia

Risk calculators and risk factors for Eosinophilic pneumonia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

Medical Therapy

  • Initial management of acute eosinophilic pneumonia (AEP) usually includes:
  • Supportive care with supplemental oxygen
  • Empiric antibiotics until culture results are available, and systemic glucocorticoid therapy[1]
  • Most patients with AEP experience progressive respiratory failure without systemic glucocorticoid therapy, but improve rapidly (within 12 to 48 hours) in response to intravenous or oral glucocorticoid therapy.[2]
  • Systemic glucocorticoids for almost all patients except those with clear evidence of an improving course.
  • Prednisone is the preferred drug of choice. Dose of 40 to 60 mg daily is reasonable.
  • In the presence of severe hypoxemia or respiratory failure requiring mechanical ventilation, methylprednisolone (60 to 125 mg every six hours) is given until respiratory failure resolves.[3]
  • Glucocorticoid tapering over 7 to 14 days may be an acceptable for patients who present with initial eosinophilia.
  • A longer treatment course up to four weeks of prednisone may occasionally be required in patients who experienced severe respiratory failure with delayed resolution of symptoms.
  • If a patient fails to respond to glucocorticoids, an alternative diagnosis should be entertained.
  • A favorable response to glucocorticoid therapy is typically defined by:[4]
  • Resolution of presenting symptoms
  • Decline in peripheral eosinophilia
  • Marked reduction of radiographic abnormalities
  • Improved pulmonary function tests evidenced by forced vital capacity (FVC), total lung capacity (TLC), diffusing capacity (DLCO), and pulse oxygen saturation.

References

  1. Hayakawa H, Sato A, Toyoshima M, Imokawa S, Taniguchi M (1994). "A clinical study of idiopathic eosinophilic pneumonia". Chest. 105 (5): 1462–6. PMID 8181338.
  2. Jantz MA, Sahn SA (1999). "Corticosteroids in acute respiratory failure". Am J Respir Crit Care Med. 160 (4): 1079–100. doi:10.1164/ajrccm.160.4.9901075. PMID 10508792.
  3. Jhun BW, Kim SJ, Kim K, Lee JE (2015). "Outcomes of rapid corticosteroid tapering in acute eosinophilic pneumonia patients with initial eosinophilia". Respirology. 20 (8): 1241–7. doi:10.1111/resp.12639. PMID 26333129.
  4. Jederlinic PJ, Sicilian L, Gaensler EA (1988). "Chronic eosinophilic pneumonia. A report of 19 cases and a review of the literature". Medicine (Baltimore). 67 (3): 154–62. PMID 3285120.

Template:WH Template:WS